BFBartosz Adam Frycz

Bartosz Adam Frycz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bartosz Adam Frycz has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Pawel Piotr Jagodzinski

    Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, 60-781 Poznań, Poland

    9 shared publications
  • Dawid Murawa

    First Department of Surgical Oncology and General Surgery, Greater Poland Cancer Centre, 61-866 Poznań, Poland

    5 shared publications
  • Michał Drews

    Department of General and Endocrine Surgery and Gastroenterological Oncology, Heliodor Święcicki Clinical Hospital, Poznań University of Medical Sciences, 60-355 Poznań, Poland

    5 shared publications
  • Paweł Murawa

    First Department of Surgical Oncology and General Surgery, Greater Poland Cancer Centre, 61-866 Poznań, Poland

    5 shared publications
  • Ryszard Marciniak

    Poznan University of Medical Sciences, Poznan, Poland

    5 shared publications
  • Maciej Borejsza-Wysocki

    Department of General and Endocrine Surgery and Gastroenterological Oncology, Heliodor Święcicki Clinical Hospital, Poznań University of Medical Sciences, 60-355 Poznań, Poland

    4 shared publications

Latest Publications

  • Open Access

    Passiflora incarnata extract-induced VEGF and TGF-β1 mRNA expression in the cardiovascular system using the rat model of type 2 diabetes

    by Anna Wesołowska, Marcin Ożarowski, Przemysław Ł. Mikołajczak, Agnieszka Stelmaszyk, Anna Maliszewska-Dworacka, Saule Iskakova, Bartosz A. Frycz, Paweł P. Jagodziński, Marzena Dworacka

    Aim. To investigate the possible effects of Passiflora extract on VEGF and TGF-β1 mRNA expression – growth factors closely related to the development of diabetes in the cardiovascular system. Material and methods. The animal model of type 2 diabetes, rich-fat/STZ Wistar rats, was used. Animals were randomised into four groups: Passiflora-treated type 2 diabetes mellitus model group; metformin-treated type 2 diabetes mellitus model group; placebo-treated type 2 diabetes mellitus model group; and placebo-treated non-diabetic control group. Passiflora incarnata leaf extract was administered orally once daily for eight consecutive weeks. mRNA VEGF, VEGF-R1, VEGF-R2 and TGF-β1 expression were measured in the myocardium and the aorta. Results. Passiflora incarnata extract increases VEGF and VEGFR2 mRNA expression in the myocardium of rats with type 2 diabetes and decreases expression in the aortal wall. The expression of TGF-β1 mRNA in both the myocardium and the aorta is reduced in Passiflora incarnata-treated rats with diabetes. Most observed effects are independent of the animals' current metabolic status. Conclusions. The current data provide novel findings on the beneficial effects of Passiflora extract on the myocardium in the context of type 2 diabetes, potentially through mechanisms involving VEGF and TGF-β1. However, the significance of the impact of Passiflora extract on the aorta wall via VEGF and TGF-β1 is uncertain.

  • Activation of trace amine‐associated receptor 1 (TAAR1) transiently reduces alcohol drinking in socially housed mice

    by Bartosz Adam Frycz, Klaudia Nowicka, Anna Konopka, Marius Christian Hoener, Ewa Bulska, Leszek Kaczmarek, Marzena Stefaniuk

    Alcohol dependence is characterized by the abnormal release of dopamine in the brain reward‐related areas. Trace amine‐associated receptor 1 (TAAR1) is a G protein‐coupled receptor that negatively regulates dopamine neurotransmission and thus is a promising target in the treatment of drug addiction. However, the role of TAAR1 in the regulation of alcohol abuse remains understudied. Here, we assessed the effect of TAAR1 activation on alcohol drinking behaviours of C57Bl/6J female mice housed in IntelliCages. The animals were administered with either vehicle or TAAR1 full selective agonist, RO5256390, and tested for alcohol consumption, alcohol preference and motivation for alcohol seeking. We found that mice with the highest preference for alcohol (high drinkers) in the RO5256390 group consumed less alcohol and had lower alcohol preference in comparison with high drinkers in the vehicle group, during 20 h of free alcohol access (FAA). We also found decreased alcohol consumption and alcohol preference comparing all animals in the RO5256390 to all animals in the vehicle group, during 20 h of FAA performed after the abstinence. These effects of RO5256390 lasted for the first 24 h after administration that roughly corresponded to the compound level in the brain, measured by mass spectrometry. Finally, we found that administration of RO5256390 may attenuate motivation for alcohol seeking. Taken together, our findings reveal that activation of TAAR1 may transiently reduce alcohol drinking; thus, TAAR1 is a promising target for the treatment of alcohol abuse and relapse.


  • Open Access

    Activation of trace amine-associated receptor 1 (TAAR1) transiently reduces alcohol drinking in socially housed mice

    by Bartosz Adam Frycz, Klaudia Nowicka, Anna Konopka, Marius Christian Hoener, Ewa Bulska, Leszek Kaczmarek, Marzena Stefaniuk

    Alcohol dependence is characterized by the abnormal release of dopamine in the brain reward-related areas. Trace amine-associated receptor 1 (TAAR1) is a G Protein-Coupled Receptor that negatively regulates dopamine neurotransmission and thus is a promising target in the treatment of drug addiction. However, the role of TAAR1 in the regulation of alcohol abuse remains understudied. Here, we assessed the effect of TAAR1 activation on alcohol-drinking behaviors of C57Bl/6J female mice housed in IntelliCages. The animals were administered with either vehicle or TAAR1 full selective agonist, RO5256390, and tested for alcohol consumption, alcohol preference, and motivation for alcohol seeking. We found that mice with the highest preference for alcohol (high drinkers) in the RO5256390 group consumed less alcohol and had lower alcohol preference in comparison to high drinkers in the vehicle group, during 20 h of free alcohol access (FAA). We also found decreased alcohol consumption and alcohol preference comparing all animals in the RO5256390 to all animals in the vehicle group, during 20 h of FAA performed after the abstinence. These effects of RO5256390 lasted for the first 24 hours after administration that roughly corresponded to the compound level in the brain, measured by mass spectrometry. Finally, we found that administration of RO5256390 may attenuate motivation for alcohol seeking. Taken together, our findings reveal that activation of TAAR1 may transiently reduce alcohol drinking; thus, TAAR1 is a promising target for the treatment of alcohol abuse and relapse.

  • Relative indoleamine 2,3-dioxygenase transcript level concerning anti-HBs titers in response to HBV vaccination in hemodialysis patients

    by Alicja E. Grzegorzewska, Bartosz A. Frycz, Hanna Winnicka, Wojciech Warchoł, Paweł P. Jagodziński

    Background: Indoleamine 2,3-dioxygenase (IDO) is a negative regulator of the immune system. To approach reasons of variability in the generation of anti-HBs antibodies in response to HBV vaccination among hemodialysis (HD) subjects, we aimed to investigate whether the IDO gene (IDO1) transcript levels are associated with post-vaccination anti-HBs production and IDO1 polymorphic variants. Methods: The IDO1 transcript was determined by qRT-PCR analysis in 110 HD patients. IDO1 (rs3739319, rs9657182) genotyping was carried out by HRM analysis. Results: The relative IDO1 transcript levels were not associated with IDO1 polymorphic variants. There were 16 non-responders (not able to produce anti-HBs >10 IU/L), 74 patients with anti-HBs 10–999 IU/L, and 20 hyperactive responders (anti-HBs ≥1000 IU/L). IDO1 transcript levels were different among these groups (0.832, 0.423–4.373; 1.114, 0.317–6.582; 0.680, 0.164–3.014; respectively, Kruskal-Wallis P = 0.024). Significance in IDO1 transcript was shown between anti-HBs titers 10–999 IU/L and ≥1000 IU/L (P = 0.020). IDO1 transcript level IDO1 transcript levels. Hyperactive anti-HBs responses occur in patients showing lower IDO1 transcript. The latter cannot be predictable by genotyping IDO1 rs3739319 or rs9657182.


  • Simvastatin attenuates the aberrant expression of angiogenic factors induced by glucose variability

    by Marzena Dworacka, Saule Iskakova, Anna Wesołowska, Gulmira Zharmakhanova, Agnieszka Stelmaszyk, Bartosz A. Frycz, Paweł P. Jagodziński, Grzegorz Dworacki


  • New arguments for beneficial effects of alpha-lipoic acid on the cardiovascular system in the course of type 2 diabetes

    by Marzena Dworacka, Galina Chukanova, Saule Iskakova, Yergen Kurmambayev, Anna Wesołowska, Bartosz A. Frycz, Paweł P. Jagodziński, Grzegorz Dworacki


  • Open Access

    mRNA expression of steroidogenic enzymes, steroid hormone receptors and their coregulators in gastric cancer

    by Bartosz Adam Frycz, Dawid Murawa, Maciej Borejsza-Wysocki, Mateusz Wichtowski, Arkadiusz Spychała, Ryszard Marciniak, Paweł Murawa, Michał Drews, Paweł Piotr Jagodziński

    Epidemiological and experimental findings suggest that the development of gastric cancer (GC) is regulated by steroid hormones. In postmenopausal women and older men, the majority of steroid hormones are produced locally in peripheral tissue through the enzymatic conversion of steroid precursors. Therefore, using reverse transcription-quantitative polymerase chain reaction analysis, the mRNA expression of genes encoding steroidogenic enzymes, including steroid sulfatase (STS), hydroxy-delta-5-steroid dehydrogenase 3 beta- and steroid delta-isomerase 1 (HSD3B1), 17β-hydroxysteroid dehydrogenase type 7 and aromatase (CYP19A1), was investigated in primary tumoral and adjacent healthy gastric mucosa from 60 patients with GC. Furthermore, the mRNA levels for estrogen receptor α, estrogen receptor β (ESR2) and androgen receptor (AR), along with their coregulators, including proline, glutamate and leucine rich protein 1, CREB binding protein, nuclear receptor coactivator 1 (NCOA1), nuclear receptor corepressor 1 (NCOR1) and nuclear receptor subfamily 2 group F member 1 (NR2F1), were investigated. Additionally, the association between the mRNA expression of these genes and the clinicopathological features of patients with GC was examined. Significantly decreased levels of STS, HSD3B1, ESR2, AR, NCOA1 and NCOR1 mRNA, in addition to significantly increased levels of CYP19A1 mRNA were demonstrated in tumoral tissue samples compared with adjacent healthy gastric tissue samples. Deregulated expression of these genes in the analyzed tissue samples was associated with certain clinicopathological features of GC, such as age and localization of the tumor. The results of the current study suggest that all of the genes analyzed are expressed in tumoral and adjacent healthy gastric mucosa. In addition, the results indicate that abnormal expression of STS, ESR2, AR, NCOA1 and NCOR1 may serve a role in the development and progression of GC, and may be associated with specific clinicopathological features in patients with GC.


  • Open Access

    Associations of the calcium-sensing receptor gene CASR rs7652589 SNP with nephrolithiasis and secondary hyperparathyroidism in haemodialysis patients

    by Alicja E. Grzegorzewska, Mateusz Paciorkowski, Adrianna Mostowska, Bartosz Frycz, Wojciech Warchoł, Ireneusz Stolarek, Marek Figlerowicz, Paweł P. Jagodziński

    Nephrolithiasis, secondary hyperparathyroidism (sHPT), and cardiovascular complications are associated with disturbances in Ca handling and contribute to morbidity/mortality during haemodialysis (HD). Calcimimetics, activators of the calcium-sensing receptor (CaSR), provide an effective means of reducing parathyroid hormone (PTH) secretion in sHPT. Polymorphism in CaSR gene (CASR) influences Ca-related parameters, however it was not shown in HD patients for CASR rs7652589. The minor allele at this polymorphism modifies the binding sites of transcription factors and CaSR expression. We hypothesized that CASR rs7652589 variants may also influence CaSR in end stage renal disease (ESRD). We aimed to determine the associations of rs7652589 with nephrolithiasis-related ESRD, Ca, P, ALP, PTH, response to treatment with cinacalcet, prevalence of coronary artery disease, and all-cause/cardiovascular mortality in HD patients (n = 1162). Healthy individuals (n = 918) were controls. This study shows that the A allele of rs7652589 is a risk allele for nephrolithiasis-related ESRD. The AA genotype is associated with more severe sHPT (higher Ca and PTH concentrations). The A allele is associated with reduced CaSR transcript level in peripheral blood mononuclear cells. According to computational analysis, potential binding sites for GLI3, AHR and TP53 are removed by the A allele, whereas binding sites for SOX18 and TP63 are created.


  • Transcript level of AKR1C3 is down-regulated in gastric cancer

    by Bartosz Adam Frycz, Dawid Murawa, Maciej Borejsza-Wysocki, Mateusz Wichtowski, Arkadiusz Spychała, Ryszard Marciniak, Paweł Murawa, Michał Drews, Paweł Piotr Jagodziński

    Steroid hormones have been shown to play a role in gastric carcinogenesis. Large amounts of steroid hormones are locally produced in the peripheral tissues of both genders. Type 5 of 17β-hydroxysteroid dehydrogenase, encoded by the AKR1C3 gene, plays a pivotal role in both androgen and estrogen metabolism, and its expression was found to be deregulated in different cancers. In this study we measured AKR1C3 transcript and protein levels in nontumoral and primary tumoral gastric tissues, and evaluated their association with some clinicopathological features of gastric cancer (GC). We found decreased levels of AKR1C3 transcript (p < 0.0001) and protein (p = 0.0021) in GC tissues compared with the adjacent, apparently histopathologically normal, mucosa. Lower levels of AKR1C3 transcript were observed in diffuse and intestinal types of GC, whereas AKR1C3 protein levels were decreased in tumors with multisite localization, in diffuse histological type, T3, T4, and G3 grades. We also determined the effect of the histone deacetylase inhibitor sodium butyrate (NaBu) on AKR1C3 expression in EPG 85-257 and HGC-27 GC cell lines. We found that NaBu elevates the levels of both AKR1C3 transcript and protein in the cell lines we investigated. Together, our results suggest that decreased expression of AKR1C3 may be involved in development of GC and can be restored by NaBu.


  • Thymic emigration patterns in patients with type 2 diabetes treated with metformin

    by Grzegorz Dworacki, Olzhas Urazayev, Yerbol Bekmukhambetov, Saule Iskakova, Bartosz A. Frycz, Paweł P. Jagodziński, Marzena Dworacka

    Summary: Recent data suggest that thymic output, which provides the naive T cells necessary for the normal functioning of T‐cell‐dependent immunosurveillance cellular immunity including anti‐cancer protection, can be disturbed in the course of type 2 diabetes. Metformin, an anti‐diabetic drug commonly confirmed as an agent with many potential anti‐cancer activities, might be helpful in this immune correction. The profile of thymic output was evaluated in the current study on the basis of the signal‐joint T‐cell receptor excision circle (sjTREC) concentration in peripheral blood polymorphonuclear cells and thymic emigrant content in peripheral blood evaluated from CD127 and/or CD132 antigen expression. It was revealed that recent thymic emigrants and more differentiated CD127+ CD132+ cell populations were decreased among naive T cells and CD8+ T cells, whereas RTE count was increased in CD4+ T cells, and the CD127+ CD132+ cell population was less numerous than in non‐diabetic participants. Terminally differentiated thymic emigrants, i.e. CD127− CD132+ cells, were increased in naive T cells and in CD8+ T cells. Metformin affects mainly the early phases of thymic export, increasing CD127+ CD132− and CD127+ CD132+ cell populations in naive T cells and the CD127+ CD132− population in CD4+ T lymphocytes. It could be concluded that type 2 diabetes deteriorates thymic immunostasis. The decreased thymic output could be compensated by metformin, especially with regard to CD4+ naive T cells. It is the first time that therapy with metformin has been documented by us as particularly useful in the control and normalization of thymus function, regarding correction of early populations of thymic emigrants.